Amylyx Pharmaceuticals’ (AMLX) Buy Rating Reaffirmed at HC Wainwright

Amylyx Pharmaceuticals (NASDAQ:AMLX)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $8.00 target price on the stock. HC Wainwright’s price target would indicate a potential upside of 349.44% from the company’s previous close.

A number of other research analysts have also commented on the stock. Leerink Partnrs lowered shares of Amylyx Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Monday, March 11th. Mizuho cut their price objective on shares of Amylyx Pharmaceuticals from $4.00 to $3.00 and set a “neutral” rating for the company in a research report on Tuesday, May 14th. The Goldman Sachs Group reaffirmed a “neutral” rating on shares of Amylyx Pharmaceuticals in a research report on Friday, March 8th. Evercore ISI reaffirmed an “in-line” rating on shares of Amylyx Pharmaceuticals in a research report on Friday, March 8th. Finally, Robert W. Baird lowered shares of Amylyx Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research report on Monday, March 11th. Six investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $28.67.

Amylyx Pharmaceuticals Trading Up 7.9 %

Amylyx Pharmaceuticals stock opened at $1.78 on Monday. The company has a market capitalization of $121.06 million, a P/E ratio of -1.66 and a beta of -0.68. The firm’s fifty day simple moving average is $1.81 and its 200-day simple moving average is $8.50. Amylyx Pharmaceuticals has a 1-year low of $1.58 and a 1-year high of $25.48.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its earnings results on Friday, May 10th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.70). The firm had revenue of $88.64 million for the quarter, compared to analyst estimates of $113.26 million. Amylyx Pharmaceuticals had a positive return on equity of 4.14% and a negative net margin of 17.86%. During the same period in the prior year, the firm earned $0.02 EPS. On average, equities research analysts predict that Amylyx Pharmaceuticals will post -1.36 earnings per share for the current year.

Institutional Trading of Amylyx Pharmaceuticals

Several large investors have recently added to or reduced their stakes in AMLX. Swiss National Bank grew its stake in Amylyx Pharmaceuticals by 1.7% during the third quarter. Swiss National Bank now owns 66,500 shares of the company’s stock worth $1,218,000 after buying an additional 1,100 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Amylyx Pharmaceuticals by 12.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 365,862 shares of the company’s stock valued at $6,699,000 after purchasing an additional 40,380 shares during the last quarter. Rafferty Asset Management LLC bought a new stake in shares of Amylyx Pharmaceuticals during the third quarter valued at approximately $207,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Amylyx Pharmaceuticals during the third quarter valued at approximately $2,279,000. Finally, Profund Advisors LLC grew its stake in shares of Amylyx Pharmaceuticals by 40.2% during the third quarter. Profund Advisors LLC now owns 19,368 shares of the company’s stock valued at $355,000 after purchasing an additional 5,558 shares during the last quarter. 95.84% of the stock is owned by institutional investors.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.